InvestWiser

BibbInstruments AB

BIBBNasdaq StockholmHealthcareMarket value 57 m SEK
0.35SEK +1.2%
last day · Price as of 17 November 2026

The answer first

Does BibbInstruments beat the market?

No, BibbInstruments has not beaten the market over the last year.

BibbInstruments−88.4%Stockholm (OMXSGI)+18.7%
  • The ranking · Quality, value and trend combined

    Better than 21% of Nordic stocks

    • Quality83
    • Value21
    • Trend4

    No. 129 of 195 in healthcare

Max for seven days

Follow BibbInstruments with Aurora

Aurora lets you know at the next report. No card.

Both with dividends. Figures as of 17 November 2026. General analysis, not personal advice.

Follow your thesis

Follow your thesis on BibbInstruments

From today, at a price of 0.35 SEK. Write why you follow BibbInstruments, and choose what Aurora should tell you about.

What should Aurora follow?

Free, no card. The mission is ready when your account is.

Aurora tells you that something happened. What you do is your choice.

Ask Aurora about BibbInstruments

Your first answer is free, no account needed.

Do you own BibbInstruments, or are you thinking about it?

See it next to the rest of your portfolio, or build your first one with BibbInstruments and a few more. Free, no card.

Past year against the exchange and Super Stock
BibbInstruments−88.4%Stockholm (OMXSGI)+18.7%Super Stock+45.9%
14 November 202517 November 2026
All start at 0 % a year ago, with dividends. Super Stock is our model portfolio: the 20 highest-ranked Nordic stocks on quality, value and trend.

In short

  • BibbInstruments has fallen 88.4% over the past year, including dividends.
  • Overall, BibbInstruments ranks better than 21% of Nordic stocks on quality, value and trend.
  • The largest fall over the past three years was 94.7%. The price is 97.7% below its peak now.

What do analysts think of BibbInstruments?

Quality, value and trend

Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.

21

Quality, value and trend together. Better than 21% of Nordic stocks.

No. 129 of 195 in healthcare

Quality83
The company · Fundamentals: the accounts

High A solid company: it earns well on its money and has healthy finances.

No. 44 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50

  • Debt to equityBorrowings divided by equity–
  • Asset turnoverSales divided by everything the company owns0.01
  • Return on equityProfit divided by equity−28.3%
  • Cash conversionOperating cash flow divided by profit–

The ranking is built on equity ratio, ROA and how steadily profit grows.

Value21
The price · Valuation: the multiples

Low High price: buyers pay a lot today, often because they expect growth.

No. 99 of 197 in healthcareTypical in healthcare: 21Typical in the Nordics: 50

  • P/BPrice divided by equity0.8
  • P/SPrice divided by sales56.5
  • P/EPrice divided by earningsnegative earnings
  • P/CFPrice divided by operating cash flownegative earnings

The ranking is built on P/E, P/B and P/S.

Trend4
The share price · Technical: the price trend

Low Headwind in the share price: it has done worse than most over the last year.

No. 185 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50

  • 3 months−42.5%
  • 6 months−30.5%
  • 9 months−84.4%
  • 12 months−88.4%

The ranking is built on 3, 6 and 12–1 months.

Return and risk

1 month
−7.7%
3 years, per year
−48.5%
5 years, per year
−48.1%
Year to date
−90.1%
Largest fall, 3 years
−94.7%
From a peak to the bottom
From the peak now
−97.7%
How far the price is from the peak
Volatility, 1 year
111.3%
How much the price swings over a year
Beta, 1 year
1.56
How much the price moves when the market moves

Return with dividends reinvested.

About BibbInstruments

BibbInstruments AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 4 employees.

BiBBInstruments AB, a medical technology company, develops and markets electrically powered endoscopic biopsy systems in the United States and Europe. The company offers EndoDrill which enables tissue sampling, with the aim of improving diagnostics in several common cancers, including those affecting the pancreas, stomach, liver, lungs, and urinary bladder. It also provides EndoDrill GI which used for endoscopic ultrasound; EndoDrill EBUS is used in the airways during endobronchial ultrasound (EBUS); and EndoDrill URO that is used with a standard cystoscope for sampling of muscle-invasive bladder cancer. The company was incorporated in 2013 and is headquartered in Lund, Sweden.

See the full analysis of BibbInstruments.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

Free forever · No card

Other healthcare stocks on Nasdaq Stockholm

Explore the stock market